Avantor Target of Unusually Large Options Trading (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) was the target of unusually large options trading on Monday. Traders purchased 26,227 put options on the company. This is an increase of 384% compared to the typical volume of 5,419 put options.

Avantor Stock Performance

Shares of Avantor stock traded down $0.27 during trading on Monday, hitting $22.02. 3,534,292 shares of the stock were exchanged, compared to its average volume of 4,685,844. Avantor has a 1-year low of $19.59 and a 1-year high of $28.00. The stock has a market capitalization of $14.98 billion, a price-to-earnings ratio of 47.93, a price-to-earnings-growth ratio of 3.97 and a beta of 1.28. The company has a fifty day moving average price of $21.69 and a 200-day moving average price of $23.46. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Institutional Trading of Avantor

Several institutional investors and hedge funds have recently bought and sold shares of AVTR. VisionPoint Advisory Group LLC boosted its stake in shares of Avantor by 5.2% during the 4th quarter. VisionPoint Advisory Group LLC now owns 156,767 shares of the company’s stock worth $3,323,000 after acquiring an additional 7,771 shares during the period. First Bank & Trust boosted its position in Avantor by 6.3% during the fourth quarter. First Bank & Trust now owns 18,899 shares of the company’s stock worth $398,000 after purchasing an additional 1,117 shares during the period. Global Retirement Partners LLC increased its holdings in shares of Avantor by 76.7% in the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after purchasing an additional 1,067 shares during the last quarter. Peregrine Capital Management LLC lifted its stake in shares of Avantor by 20.7% during the 4th quarter. Peregrine Capital Management LLC now owns 857,538 shares of the company’s stock worth $18,068,000 after buying an additional 147,202 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its stake in shares of Avantor by 504.8% during the 4th quarter. Venturi Wealth Management LLC now owns 7,572 shares of the company’s stock worth $160,000 after buying an additional 6,320 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

AVTR has been the subject of a number of research analyst reports. UBS Group reaffirmed a “neutral” rating and issued a $25.00 target price (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Barclays increased their price objective on Avantor from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Monday. Raymond James cut their target price on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Wells Fargo & Company decreased their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Finally, Robert W. Baird reduced their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.46.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.